The OsteoFlo HydroPutty synthetic bone graft is designed to enhance surgical outcomes. Credit: Business Wire/ Surgentec.

SurGenTec has announced 510(k) clearance from the US Food and Drug Administration (FDA) for its OsteoFlo HydroPutty Synthetic Bone Graft.

OsteoFlo HydroPutty is a hydrophilic synthetic bone graft intended to absorb fluids such as bone marrow aspirate, blood or saline.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The product’s proprietary hydrophilic carriers enable it to transform into a putty-like substance, providing surgeons with superior handling characteristics and an optimised resorption profile for bone growth.

SurGenTec founder and CEO Travis Greenhalgh said: “We are thrilled to add OsteoFlo HydroPutty to our portfolio. Its unique hydrophilic bonds enable the attachment of growth factors and provide an ideal scaffolding for bone growth.

“This product underscores our commitment to developing next-generation solutions for physicians and patients.”

The OsteoFlo HydroPutty product is presented in a sterile vial as a dry formulation and comes with a mixing spatula.  

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

When fluid is added, the hydrophilic bonds quickly absorb it, creating a putty that is easy to handle, can be packed into bone voids, resists irrigation and is compatible with SurGenTec’s Graftgun bone graft delivery system.

Duly Health and Care spine surgery chairman Dr Ashish Patel said: “OsteoFlo HydroPutty, with its ability to absorb autologous blood products and its ease of use, fills a critical gap in the realm of synthetic bone grafts.

“Its unique capability to blend with allograft and flow through small apertures makes it extremely useful when performing both open and minimally invasive surgical procedures.”

Pre-clinical studies, both short-term and long-term, have demonstrated ‘excellent bone growth and integration’ at all time points, indicating the potential of OsteoFlo HydroPutty to significantly impact patient care.

In October 2023, SurGenTec’s posterior sacroiliac joint fusion system, TiLink-P, obtained clearance from the FDA.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact